Fintepla

Fintepla, also known by its generic name fenfluramine, is a prescription medication used to treat seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years of age and older. It is an oral solution that is taken by mouth. Fintepla works by affecting neurotransmitters in the brain, which are chemical messengers that help regulate nerve activity. By modulating these neurotransmitters, the medication aims to reduce the frequency of seizures.

The development of fenfluramine has a history that includes its use in weight loss medications in the past, often in combination with phentermine. However, concerns regarding serious cardiac valve problems and pulmonary hypertension led to its withdrawal from the market for those indications in the late 1990s. Current research and clinical trials have focused on its efficacy and safety specifically for epilepsy, particularly severe forms like LGS, where the potential benefits are weighed against the risks.

Fintepla is typically prescribed as part of a comprehensive treatment plan for LGS, which may also include other anti-epileptic drugs and dietary management. The dosage is determined by a healthcare professional based on the patient's age, weight, and response to the medication. As with any medication, Fintepla can have side effects. Common side effects may include decreased appetite, diarrhea, fatigue, and somnolence. More serious potential side effects, including cardiac valvulopathy and pulmonary arterial hypertension, require careful monitoring by a physician. Patients taking Fintepla undergo regular cardiac evaluations to detect any early signs of these conditions. It is crucial for patients and caregivers to discuss all potential risks and benefits with their doctor before starting treatment.